diabetes. Type 2 diabetes mellitus with unspecified complications
Conditions
Interventions
Intervention 1: Intervention group:Take 800 mg of green coffee supplement daily, two 400 mg tablets daily. Intervention 2: Control group: Receive two placebos daily.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 69 Years
Inclusion criteria
Inclusion criteria: Definitive diagnosis of type 2 diabetes in patients was made by an associate clinical physician under ADA criteria. Duration of type 2 diabetes is at least 3 years The type and dose of drugs used in the last 6 months is constant No chronic (chronic, renal, hepatic, pulmonary, or chronic or acute inflammatory diseases, especially acute inflammation of the pancreas and endocarditis)No heart disease, short bowel syndrome, allergies and thyroid disease Do not use any dietary supplements in the last 6 months No pregnancy and lactation Willingness to participate in the study No allergies to green coffee
Exclusion criteria
Exclusion criteria: Pregnancy during the study period Changes in medication dosage during the study period Occurrence of one of the above diseases during the study period Dissatisfaction with continuing to participate in the study Do not take less than 80% of the allocated amount of green coffee tablets or do not follow the study design for more than a week
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Glu. Timepoint: at the first and end of the study. Method of measurement: Fasting blood glucose by glucose oxidase method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: First week 4 and week 8 study. Method of measurement: Weight of people in light clothing without shoes and in the fasting state was measured by a digital scale (model 703 Seka) with an accuracy of 100 grams.;Insulin sensitivity. Timepoint: at the first and end of the study. Method of measurement: HOMA Homeostasis.;Lipid profile. Timepoint: at the first and end of the study. Method of measurement: Triglycerides, cholesterol and LDL by enzymatic and calorimetric methods using Roach II commercial kits, HDL by calorimetric enzymatic method using Cubas Roach commercial kits.;Insulin sensitivity. Timepoint: at the first and end of the study. Method of measurement: Insulin was evaluated by chemiluminescence method (40). Insulin concentration was determined using the ELISA kit of the American company Monobind. Also, insulin resistance and its components were calculated using the HOMA Homeostasis Model (Index assessment) before and after the intervention as follows: Fasting insulin (microu / L) x fasting glucose (nmol / L) /22.5.;Total antioxidant. Timepoint: at the first and end of the study. Method of measurement: The Ferric Reducing Ability of Plasma method was determined using the main ingredient tripyridyl-S-triazine. Total antioxidant capacity was measured using 40 mM hydrochloric acid, 3-aqueous, 6-aqueous sodium acetate and triazine solution at concentrated Fecl acetic acid at 593 nm. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZohre mazloom
Shiraz University of Medical Sciences
Outcome results
None listed